iCIK过继性细胞治疗口腔鳞状细胞癌的回顾性研究

目的研究改良的细胞因子诱导杀伤细胞（iCIK）过继性治疗口腔鳞状细胞癌（OSCC）的疗效。方法回顾2008年7月至2013年4月60例OSCC患者，根据治疗方式分为iCIK组（手术治疗＋iCIK治疗）及对照组（手术治疗），不良预后者术后行放疗或放化疗。统计两组的复发转移率、生存率、无病生存期及总生存期。分析iCIK组培养前后外周血单个核细胞（PBMC）及iCIK细胞的T细胞亚群比例及Th1细胞因子分泌水平。结果 iCIK组复发转移率低于对照组（16.67％vs 40.00％，χ2＝4.022， P＝0.045），且无病生存期高于对照组（50.96±3.69 vs 38.15±4.90，χ2＝4.163，P＝0.041）。但两组的死亡率及总体生存期差异无统计学意义。 iCIK培养后T细胞及CTL细胞比例、IL-2及IFN-γ水平显著增高。不良反应发生率为1.17％，无严重不良反应。结论 iCIK辅助治疗可延长OSCC患者无病生存期，减少复发或转移的发生，但未改变最终的预后，长期疗效有待进一步观察。 iCIK高表达CD3＋CD8＋，分泌高浓度的Th1细胞因子，具有较强的细胞免疫及抗肿瘤能力，且治疗安全性良好。

A retrospective study of iCIK adoptive cellular therapy on patients with oral squamous cell carcinoma

Objective To investigate effect of improved cytokine-induced killer cells （iCIK） adoptive cellular therapy on patients with oral squamous cell carcinoma （OSCC）. Methods Sixty OSCC patients between 2008 July to 2013 April have been surveyed retrospectively and are classified into iCIK group （surgery and iCIK therapy） or Control group （surgery）. Those with adverse features received radiotherapy or chemo-radiotherapy additionally. The recurrence or metastasis rate, survival rate, disease-free survival time （DFS） and overall survival time （OS） of two groups are compared. In iCIK group, percentage of T cells subpopulations and concentrations of Th1 cell cytokines are detected between peripheral blood mononuclear cells （PBMC） and iCIK. Results The recurrence or metastasis rate in iCIK group is lower than that of the Control （16.67% vs 40.00%,χ2=4.022, P=0.045）. Meanwhile, the DFS means of the former is longer than that of the latter （50.96 ± 3.69 vs 38.15 ± 4.90, χ2=4.163, P=0.041）. Unfortunately, it has no significant difference between two groups in death rate and OS . After iCIK cultured, the percentages of T cell and CTL subpopulations, concentrations of IL-2 and IFN-γ of iCIK have been enhanced. Adverse reaction rate is 1.17%, without severe toxic effect. Conculsions iCIK prolong DFS and reduce the risk of recurrence and metastasis in OSCC . But it cannot improve prognosis significantly and acquire continuous observation to evaluate for long-term therapeutic efficacy . iCIK, a major subset of CD3＋CD8＋, are able to secrete high concentration of Th1 cell cytokines to eradicate or reduce tumor in cellular immunity. iCIK is a potential reliable therapy in safety.